Lexicon Pharmaceuticals Inc. (LXRX) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Lexicon Pharmaceuticals I... (LXRX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.69

-0.00 (-0.27%)

At close: Jan 15, 2025, 11:41 AM

undefined% (undefined)

Bid	0.69
Market Cap	250.73M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.74
PE Ratio (ttm)	-0.94
Forward PE	n/a
Analyst	Hold

Ask	0.69
Volume	1,028,569
Avg. Volume (20D)	4,721,159
Open	0.70
Previous Close	0.69
Day's Range	0.68 - 0.73
52-Week Range	0.62 - 3.73
Beta	undefined

About LXRX

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The compan...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Apr 7, 2000

Employees 285

Stock Exchange NASDAQ

Ticker Symbol LXRX

Website https://www.lexpharma.com

Analyst Forecast

According to 2 analyst ratings, the average rating for LXRX stock is "Hold." The 12-month stock price forecast is $6, which is an increase of 765.05% from the latest price.

Buy 50.00%

Hold 50.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Lexicon Pharmaceuticals Inc. is scheduled to release its earnings on Mar 10, 2025, before market opens.
Analysts project revenue of $6.48M, reflecting a 823.08% YoY growth and earnings per share of -0.12, making a -40.00% decrease YoY.

Why Price Moved

2 months ago · Source

-8.4%

Lexicon Pharmaceuticals shares are trading lower a... Unlock content with Pro Subscription

10 months ago · Source

+29.49%

Lexicon shares are trading higher after the company said it is preparing to resubmit its Sotagliflozin NDA for Type 1 diabetes following FDA feedback. Additionally, the company announced a securities purchase agreement expected to result in gross proceeds of around $250 million.

News

3 weeks ago · reuters.com

US FDA declines to approve Lexicon Pharma's add-on diabetes drug

The U.S. Food and Drug Administration declined to approve Lexicon Pharmaceuticals' add-on drug for type 1 diabetes and chronic kidney disease, the company said on Friday.

1 month ago · reuters.com

Lexicon Pharmaceuticals to cut workforce by 60% to focus on drug development

Lexicon Pharmaceuticals said on Friday it would reduce its workforce by about 60%, effective Dec. 31, to eliminate commercial activities and focus on drug development.

2 months ago · seekingalpha.com

Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2024 Earnings Call Transcript

Start Time: 17:00 January 1, 0000 5:55 PM ET Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q3 2024 Earnings Call November 12, 2024, 17:00 PM ET Company Participants Mike Exton - CEO and Director Tom Ga...

2 months ago · zacks.com

Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Lags Revenue Estimates

Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.21 per share a year ago.

2 months ago · reuters.com

FDA advisers vote against Lexicon Pharma's add-on drug for type 1 diabetes

Independent advisers to the U.S. Food and Drug Administration on Thursday voted against recommending Lexicon Pharmaceuticals' add-on treatment to insulin therapy for managing blood glucose levels in a...